EUR 1.6
(-4.88%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 118.01 Million USD | 6.28% |
2022 | 111.03 Million USD | 2.28% |
2021 | 108.56 Million USD | -5.56% |
2020 | 114.96 Million USD | 27.96% |
2019 | 89.84 Million USD | 16.27% |
2018 | 77.27 Million USD | 5.51% |
2017 | 73.23 Million USD | 39.88% |
2016 | 52.35 Million USD | 18.36% |
2015 | 44.23 Million USD | 40.25% |
2014 | 31.54 Million USD | -20.37% |
2013 | 39.6 Million USD | 0.0% |
2012 | - USD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 118.55 Million USD | 0.0% |
2023 Q2 | 114.18 Million USD | 0.0% |
2023 Q4 | 118.01 Million USD | 0.0% |
2022 Q2 | 100.92 Million USD | 0.0% |
2022 Q4 | 111.03 Million USD | 0.0% |
2022 FY | 111.03 Million USD | 2.28% |
2021 Q4 | 108.56 Million USD | 0.0% |
2021 Q2 | 112.99 Million USD | 0.0% |
2021 Q3 | - USD | -100.0% |
2021 FY | 108.56 Million USD | -5.56% |
2020 Q4 | 114.96 Million USD | 1.38% |
2020 FY | 114.96 Million USD | 27.96% |
2020 Q1 | 84.96 Million USD | -5.43% |
2020 Q2 | 112.51 Million USD | 32.42% |
2020 Q3 | 113.4 Million USD | 0.79% |
2019 Q2 | 73.07 Million USD | 0.04% |
2019 Q1 | 73.04 Million USD | -5.48% |
2019 FY | 89.84 Million USD | 16.27% |
2019 Q4 | 89.84 Million USD | 2.46% |
2019 Q3 | 87.68 Million USD | 20.0% |
2018 Q2 | 68.46 Million USD | -5.83% |
2018 Q1 | 72.7 Million USD | -0.73% |
2018 FY | 77.27 Million USD | 5.51% |
2018 Q4 | 77.27 Million USD | 18.27% |
2018 Q3 | 65.33 Million USD | -4.57% |
2017 Q3 | 69.81 Million USD | -1.66% |
2017 Q1 | 55.85 Million USD | 6.68% |
2017 FY | 73.23 Million USD | 39.88% |
2017 Q4 | 73.23 Million USD | 4.9% |
2017 Q2 | 70.99 Million USD | 27.1% |
2016 Q2 | 56.58 Million USD | -0.09% |
2016 FY | 52.35 Million USD | 18.36% |
2016 Q4 | 52.35 Million USD | -8.03% |
2016 Q3 | 56.92 Million USD | 0.6% |
2016 Q1 | 56.63 Million USD | 28.04% |
2015 Q1 | - USD | -100.0% |
2015 FY | 44.23 Million USD | 40.25% |
2015 Q4 | 44.23 Million USD | 0.0% |
2015 Q2 | 31.92 Million USD | 0.0% |
2014 Q3 | 32.88 Million USD | 0.0% |
2014 Q4 | 31.54 Million USD | -4.09% |
2014 Q1 | - USD | 0.0% |
2014 FY | 31.54 Million USD | -20.37% |
2013 FY | 39.6 Million USD | 0.0% |
2012 FY | - USD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Boiron SA | 590.2 Million EUR | 80.004% |
Laboratorios Farmaceuticos Rovi, S.A. | 799.88 Million EUR | 85.246% |
Vetoquinol SA | 692.23 Million EUR | 82.951% |
Valneva SE | 469.39 Million EUR | 74.857% |
AB Science S.A. | 25.49 Million EUR | -362.831% |
Nanobiotix S.A. | 93.89 Million EUR | -25.688% |
PHAXIAM Therapeutics S.A. | 51.3 Million EUR | -130.022% |
Vivoryon Therapeutics N.V. | 30.82 Million EUR | -282.813% |
BioSenic S.A. | 9.55 Million EUR | -1134.62% |
ABIVAX Société Anonyme | 327.06 Million EUR | 63.916% |
Formycon AG | 890.36 Million EUR | 86.745% |